Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.4
5.2
Journals
Cancers
Special Issues
The Anglesio Prize in Cancer Epidemiology and Cancer Registration
share announcement

The Anglesio Prize in Cancer Epidemiology and Cancer Registration

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Epidemiology and Prevention".

Deadline for manuscript submissions: closed (30 April 2024) | Viewed by 1677

Special Issue Editor

Dr. Stefano Rosso

E-Mail Website
Guest Editor
Piedmont Cancer Registry, Department of Medical Science, University of Turin, 10123 Turin, Italy
Interests: cancer research; public health

Special Issue Information

Dear Colleagues,

This Special Issue is dedicated to the Winners of the year 2023 Edition of Enrico Anglesio Prize https://www.fondoelenamoroni.org/en/the-prize/. This International Prize is awarded to young researchers for their original work in cancer epidemiology, and cancer registration. Evaluation was based on scientific relevance, originality, methodological correctness and how the study message was delivered. 

The year 2023 Edition proposes studies tackling novel methods that, with the help of Artificial Intelligence, aim to detect rare but adverse events among cancer survivors. With this approach, clinicians can combine population-based cancer registry data with clinical data, tailoring patient follow-ups. Methodological issues are also prominent in survival studies; lead-time bias constitutes an important effect that should be accounted for in survival estimates. A proposal of correction methods, using current information on detection circumstances, could be an interesting proposal to be discussed.

Tools for detecting pre-clinical conditions that lead to neoplasm transformation are always needed for tailoring prevention and fighting malignant evolution. In particular conditions, such as the Down Syndrome, the elevated risk of subsequent hematological neoplasms requires the monitoring of several parameters that need to be calibrated in order to improve earlier detection.

Finally, it is well known that cancer incidence, but also survival, can be affected by factors that are outside the realm of treatment and health care, but are equally important, such as inequality in socio-economic factors and factors that impact all of society, as demonstrated by COVID-19. Measuring the effect of such factors on survival or quality of life and health care is still an important mission of epidemiological studies.

Dr. Stefano Rosso
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • survival
  • prognostic factors
  • lead-time down syndrome
  • socio-economic inequalities

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

13 pages, 825 KiB  
Article
Lead-Time Corrected Effect on Breast Cancer Survival in Germany by Mode of Detection
by Laura Schumann, Moritz Hadwiger, Nora Eisemann and Alexander Katalinic
Cancers 2024, 16(7), 1326; https://doi.org/10.3390/cancers16071326 - 28 Mar 2024
Viewed by 426
Abstract
(1) Background: Screen-detected breast cancer patients tend to have better survival than patients diagnosed with symptomatic cancer. The main driver of improved survival in screen-detected cancer is detection at earlier stage. An important bias is introduced by lead time, i.e., the time span [...] Read more.
(1) Background: Screen-detected breast cancer patients tend to have better survival than patients diagnosed with symptomatic cancer. The main driver of improved survival in screen-detected cancer is detection at earlier stage. An important bias is introduced by lead time, i.e., the time span by which the diagnosis has been advanced by screening. We examine whether there is a remaining survival difference that could be attributable to mode of detection, for example, because of higher quality of care. (2) Methods: Women with a breast cancer (BC) diagnosis in 2000–2022 were included from a population-based cancer registry from Schleswig-Holstein, Germany, which also registers the mode of cancer detection. Mammography screening was available from 2005 onwards. We compared the survival for BC detected by screening with symptomatic BC detection using Kaplan–Meier, unadjusted Cox regressions, and Cox regressions adjusted for age, grading, and UICC stage. Correction for lead time bias was carried out by assuming an exponential distribution of the period during which the tumor is asymptomatic but screen-detectable (sojourn time). We used a common estimate and two recently published estimates of sojourn times. (3) Results: The analysis included 32,169 women. Survival for symptomatic BC was lower than for screen-detected BC (hazard ratio (HR): 0.23, 95% confidence interval (CI): 0.21–0.25). Adjustment for prognostic factors and lead time bias with the commonly used sojourn time resulted in an HR of 0.84 (CI: 0.75–0.94). Using different sojourn times resulted in an HR of 0.73 to 0.90. (4) Conclusions: Survival for symptomatic BC was only one quarter of screen-detected tumors, which is obviously biased. After adjustment for lead-time bias and prognostic variables, including UICC stage, survival was 27% to 10% better for screen-detected BC, which might be attributed to BC screening. Although this result fits quite well with published results for other countries with BC screening, further sources for residual confounding (e.g., self-selection) cannot be ruled out. Full article
(This article belongs to the Special Issue The Anglesio Prize in Cancer Epidemiology and Cancer Registration)
►▼ Show Figures

Figure 1

17 pages, 1915 KiB  
Article
How Did Breast Cancer Patients Fare during Different Phases of the COVID-19 Pandemic in Norway Compared to Age-Matched Controls?
by Karianne Svendsen, Sigrid Leithe, Cassia B. Trewin-Nybråten, Aina Balto, Lise Solberg Nes, Anders Meland, Elin Børøsund, Cecilie E. Kiserud, Kristin Valborg Reinertsen, Hege R. Eriksen, Ylva Maria Gjelsvik and Giske Ursin
Cancers 2024, 16(3), 602; https://doi.org/10.3390/cancers16030602 - 31 Jan 2024
Viewed by 1031
Abstract
Little is known about how health-related quality of life (HRQoL) in breast cancer cases differed from that of controls during and after the COVID-19 pandemic. This study used data from an ongoing, nationwide HRQoL survey of 4279 newly diagnosed breast cancer cases and [...] Read more.
Little is known about how health-related quality of life (HRQoL) in breast cancer cases differed from that of controls during and after the COVID-19 pandemic. This study used data from an ongoing, nationwide HRQoL survey of 4279 newly diagnosed breast cancer cases and 2911 controls to investigate how breast cancer patients fared during different phases of the pandemic compared to controls. Responders during 2020–2022 were categorized into three COVID-19-related phases: the social restrictions phase, the high infection rate phase, and the post-pandemic phase. Across phases, breast cancer cases had significantly worse scores in most HRQoL domains compared to controls. Apart from slightly more insomnia in the high infection rate phase for both cases and controls, and better social functioning for young cases in the post-COVID-19 phase, the case-control differences in HRQoL remained consistent across phases. When the phases were assessed as one period, young women and those living with children <18 years of age fared the worst among breast cancer cases, while single women fared the worst among controls. In contrast, controls living with children <18 years of age exhibited better HRQoL than controls without children. In summary, women with breast cancer did not appear to fare differently than controls in terms of HRQoL across COVID-19 phases. However, breast cancer cases with young children fared worse in their HRQoL than other breast cancer cases. Full article
(This article belongs to the Special Issue The Anglesio Prize in Cancer Epidemiology and Cancer Registration)
►▼ Show Figures

Graphical abstract

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop